HRP20180027T1 - Protutijela za neutraliziranje virusa ljudske imunodeficijencije (hiv) - Google Patents
Protutijela za neutraliziranje virusa ljudske imunodeficijencije (hiv) Download PDFInfo
- Publication number
- HRP20180027T1 HRP20180027T1 HRP20180027TT HRP20180027T HRP20180027T1 HR P20180027 T1 HRP20180027 T1 HR P20180027T1 HR P20180027T T HRP20180027T T HR P20180027TT HR P20180027 T HRP20180027 T HR P20180027T HR P20180027 T1 HRP20180027 T1 HR P20180027T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- hiv
- antigen
- binding fragment
- clade
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims 3
- 239000012634 fragment Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 230000004988 N-glycosylation Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700004025 env Genes Proteins 0.000 claims 1
- 101150030339 env gene Proteins 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000002064 post-exposure prophylaxis Effects 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (24)
1. Protutijelo protiv HIV-a, naznačeno time što je navedeno protutijelo PG9, koji ima teški lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 39, i laki lanac, koji sadrži aminokiselinski slijed SEQ ID NO: 40.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je protutijelo ljudsko ili humanizirano monoklonsko protutijelo.
3. Protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što protutijelo neutralizira vrste HIV-1 koje pripadaju u dva ili više kladova, te što se potentnost neutraliziranja najmanje jednog člana svakog klada određuje vrijednošću IC50 manjom od 0,2 µg/ml.
4. Protutijelo u skladu s patentnim zahtjevom 3, naznačeno time što protutijelo neutralizira HIV-1 koji pripada u dva ili više kladova, koje se bira između Klada A, Klada B, Klada C, Klada D i Klada AE.
5. Protutijelo u skladu s patentnim zahtjevom 4, naznačeno time što su HIV-1 koji pripadaju u dva ili više kladova virusi koji ne pripadaju Kladu B.
6. Protutijelo u skladu s patentnim zahtjevom 4, naznačeno time što protutijelo (a) neutralizira najmanje jedan član svakog klada s potentnošću većom od one za bNAbs b12, 2G12, 2F5 odnosno 4E10, (b) ne veže se na monomerne proteine gp120 ili gp41 iz HIV-1 env gena ili (c) veže se većim afinitetom prema trimernim oblicima HIV-1 Env koji se eksprimiraju na površini stanice nego prema monomernom gp120 ili gp140 trimeriziranom na umjetan način.
7. Protutijelo u skladu s patentnim zahtjevom 6, naznačeno time što se protutijelo veže s visokim afinitetom na necijepane HIV-1 trimere gp160 na površini stanice.
8. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačeno time što se protutijelo veže na epitop u varijabilnoj omči gp120, gdje epitop sadrži očuvana područja omči V2 i V3 u gp120.
9. Protutijelo u skladu s patentnim zahtjevom 8, naznačen time što epitop sadrži N-glikozilacijsko mjesto na ostatku Asn-160 u omči V2 u gp120.
10. Protutijelo u skladu s patentnim zahtjevom 8, naznačen time što protutijelo ne neutralizira HIV-1 u odsutnosti N-glikozilacijskog mjesta na ostatku Asn-160 u omči V2 u gp120.
11. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačeno time što se protutijelo veže na epitop kojeg prezentira trimerni šiljak gp120 na površini stanice, gdje se epitop ne prezentira kada je gp120 trimeriziran na umjetan način.
12. Antigenski vežući fragment, naznačen time što je fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
13. Antigenski vežući fragment u skladu s patentnim zahtjevom 12, naznačen time što se bira iz skupine koju čine fragmenti Fab, Fab’, F(ab’)2, Fv, jednolančanog Fv, dijatijela i jedne varijabilne domene imunoglobulina.
14. Molekula nukleinske kiseline, naznačena time što kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegov antigenski vežući fragment u skladu s patentnim zahtjevom 12 ili 13.
15. Vektor, naznačen time što sadrži molekulu nukleinske kiseline u skladu s patentnim zahtjevom 14.
16. Stanica, naznačena time što sadrži vektor u skladu s patentnim zahtjevom 15.
17. Imortalizirani klon B-stanica, naznačen time što eksprimira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
18. Farmaceutski pripravak, naznačen time što u najmanju ruku sadrži protutijelo ili antigenski vežući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 13, kao i farmaceutski prihvatljiv nosač.
19. Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što dodatno sadrži drugo protutijelo ili antigenski vežući fragment specifičan za drugi epitop.
20. Protutijelo ili antigenski vežući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačeni time što su namijenjeni upotrebi u liječenju ili slabljenju učinka zaraze HIV-om ili bolesti povezane s HIV-om ili u profilaksi nakon izlaganja.
21. Protutijelo ili antigenski vežući fragment, namijenjeni upotrebi u skladu s patentnim zahtjevom 20, naznačeni time što se primjenjuje drugo terapijsko sredstvo.
22. Protutijelo ili antigenski vežući fragment, namijenjeni upotrebi u skladu s patentnim zahtjevom 21, naznačeni time što je navedeno drugo terapijsko sredstvo protuvirusno sredstvo.
23. Protutijelo ili antigenski vežući fragment u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačeni time što su namijenjeni upotrebi u liječenju osobe od više vrsta HIV-1.
24. Postupak proizvodnje protutijela u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u: (i) uzgoju imortalizirani klon B-stanica koji eksprimira protutijelo u skladu s patentnim zahtjevom 1 i (ii) izdvajanju protutijela
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16101009P | 2009-03-17 | 2009-03-17 | |
| US16582909P | 2009-04-01 | 2009-04-01 | |
| US22473909P | 2009-07-10 | 2009-07-10 | |
| US28566409P | 2009-12-11 | 2009-12-11 | |
| EP10722810.8A EP2408476B1 (en) | 2009-03-17 | 2010-03-17 | Human immunodeficiency virus (hiv) -neutralizing antibodies |
| PCT/US2010/027695 WO2010107939A2 (en) | 2009-03-17 | 2010-03-17 | Human immunodeficiency virus (hiv) -neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180027T1 true HRP20180027T1 (hr) | 2018-04-20 |
Family
ID=42668183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180027TT HRP20180027T1 (hr) | 2009-03-17 | 2018-01-08 | Protutijela za neutraliziranje virusa ljudske imunodeficijencije (hiv) |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US9051362B2 (hr) |
| EP (5) | EP2408476B1 (hr) |
| AU (5) | AU2010226668B2 (hr) |
| CA (2) | CA2755821C (hr) |
| CY (1) | CY1121323T1 (hr) |
| DK (1) | DK2408476T3 (hr) |
| ES (4) | ES2848555T3 (hr) |
| HR (1) | HRP20180027T1 (hr) |
| HU (1) | HUE036031T2 (hr) |
| LT (1) | LT2408476T (hr) |
| NO (1) | NO2408476T3 (hr) |
| PL (4) | PL3542817T3 (hr) |
| PT (4) | PT2408476T (hr) |
| SI (4) | SI3260136T1 (hr) |
| WO (1) | WO2010107939A2 (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2623794T3 (es) | 2008-12-09 | 2017-07-12 | Gilead Sciences, Inc. | Intermedios para la preparación de moduladores de receptores tipo toll |
| WO2011092593A2 (en) * | 2010-01-20 | 2011-08-04 | Institute For Research In Biomedicine | Hiv-1 neutralizing antibodies and uses thereof |
| WO2011109511A2 (en) * | 2010-03-02 | 2011-09-09 | International Aids Vaccine Initiative | Novel hiv-1 envelope glycoprotein |
| PT3556396T (pt) * | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
| WO2012040562A2 (en) | 2010-09-24 | 2012-03-29 | International Aids Vaccine Initiative | Novel hiv-1 broadly neutralizing antibodies |
| EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
| US10040826B2 (en) | 2011-07-05 | 2018-08-07 | Duke University | Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens |
| US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
| EP2763699A4 (en) * | 2011-10-03 | 2015-05-20 | Univ Duke | VACCINE |
| US9988424B2 (en) | 2011-12-05 | 2018-06-05 | Duke University | Immunogens comprising human immunodeficiency virus V1/V2 polypeptides |
| CN108676091B (zh) | 2011-12-08 | 2022-04-01 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| US20150044137A1 (en) * | 2012-03-23 | 2015-02-12 | The United States of America, as represented by the Secretary, Dep. of Health Care Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
| WO2014134547A1 (en) * | 2013-02-28 | 2014-09-04 | Therabiol, Inc. | Hiv antigens and antibodies |
| US20160130328A1 (en) * | 2013-06-17 | 2016-05-12 | Emory University | Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications |
| WO2015048517A1 (en) * | 2013-09-28 | 2015-04-02 | Duke University | Escape mutants |
| WO2015127108A1 (en) * | 2014-02-19 | 2015-08-27 | Duke University | Trimeric hiv-1 envelopes compositions and uses thereof |
| US10093720B2 (en) * | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| PL3166607T3 (pl) | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych do leczenia hiv |
| CN106715431A (zh) | 2014-09-16 | 2017-05-24 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
| WO2016054023A1 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Hiv-1 antibodies and uses thereof (adcc and bispecific abs) |
| MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
| BR112018005931A2 (pt) | 2015-09-24 | 2018-10-09 | Abvitro Llc | composições de anticorpo para hiv e métodos de uso |
| WO2017106346A2 (en) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
| CN107022027B (zh) * | 2016-02-02 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| CN107033241B (zh) * | 2016-02-03 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
| EP3641806A4 (en) * | 2017-06-22 | 2021-06-23 | University of Maryland, Baltimore | BROAD NEUTRALIZING ANTIBODIES AGAINST HIV |
| JP7126573B2 (ja) | 2018-07-03 | 2022-08-26 | ギリアード サイエンシーズ， インコーポレイテッド | ＨＩＶ ｇｐ１２０を標的化する抗体および使用方法 |
| WO2020082045A1 (en) * | 2018-10-19 | 2020-04-23 | University Of Maryland, College Park | Multispecfic anti-hiv antibodies |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| US20230134571A1 (en) * | 2019-10-29 | 2023-05-04 | International Aids Vaccine Initiative | Engineered antibodies to hiv env |
| US20210277093A1 (en) * | 2020-03-09 | 2021-09-09 | Adma Biologics, Inc. | Immunotherapeutic compositions and methods of production for coronavirus |
| JP2023539196A (ja) | 2020-08-25 | 2023-09-13 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022162009A1 (en) | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
| WO2022161597A1 (en) * | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
| WO2022225875A1 (en) * | 2021-04-19 | 2022-10-27 | The Wistar Institute Of Anatomy And Biology | Sialydase linked hiv antibodies and methods of use |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
| EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| EP1241264A1 (en) | 1994-12-02 | 2002-09-18 | Chiron Corporation | Monoclonal antibodies to colon cancer antigen |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| JP4773947B2 (ja) | 2003-01-09 | 2011-09-14 | マクロジェニクス，インコーポレーテッド | 細菌細胞及び哺乳動物細胞における抗体発現のための二重発現ベクター系 |
| EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| AU2005302416A1 (en) * | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies |
| PT3556396T (pt) * | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
-
2010
- 2010-03-01 SI SI201032049T patent/SI3260136T1/sl unknown
- 2010-03-17 HU HUE10722810A patent/HUE036031T2/hu unknown
- 2010-03-17 SI SI201032112T patent/SI3542817T1/sl unknown
- 2010-03-17 SI SI201031616T patent/SI2408476T1/en unknown
- 2010-03-17 PT PT107228108T patent/PT2408476T/pt unknown
- 2010-03-17 PT PT182077073T patent/PT3542817T/pt unknown
- 2010-03-17 CA CA2755821A patent/CA2755821C/en active Active
- 2010-03-17 LT LTEP10722810.8T patent/LT2408476T/lt unknown
- 2010-03-17 WO PCT/US2010/027695 patent/WO2010107939A2/en active Application Filing
- 2010-03-17 SI SI201032062T patent/SI3323427T1/sl unknown
- 2010-03-17 AU AU2010226668A patent/AU2010226668B2/en active Active
- 2010-03-17 PL PL18207707.3T patent/PL3542817T3/pl unknown
- 2010-03-17 PL PL17194834T patent/PL3323427T3/pl unknown
- 2010-03-17 DK DK10722810.8T patent/DK2408476T3/en active
- 2010-03-17 PL PL17173548T patent/PL3260136T3/pl unknown
- 2010-03-17 ES ES17173548T patent/ES2848555T3/es active Active
- 2010-03-17 NO NO10722810A patent/NO2408476T3/no unknown
- 2010-03-17 ES ES10722810.8T patent/ES2656234T3/es active Active
- 2010-03-17 EP EP10722810.8A patent/EP2408476B1/en active Active
- 2010-03-17 PT PT171948342T patent/PT3323427T/pt unknown
- 2010-03-17 US US12/726,245 patent/US9051362B2/en active Active
- 2010-03-17 ES ES17194834T patent/ES2848203T3/es active Active
- 2010-03-17 PT PT171735483T patent/PT3260136T/pt unknown
- 2010-03-17 EP EP18207707.3A patent/EP3542817B1/en active Active
- 2010-03-17 PL PL10722810T patent/PL2408476T3/pl unknown
- 2010-03-17 EP EP17173548.3A patent/EP3260136B1/en active Active
- 2010-03-17 EP EP22171792.9A patent/EP4085925A1/en active Pending
- 2010-03-17 EP EP17194834.2A patent/EP3323427B1/en active Active
- 2010-03-17 CA CA2980883A patent/CA2980883C/en active Active
- 2010-03-17 ES ES18207707T patent/ES2916404T3/es active Active
-
2015
- 2015-04-21 US US14/692,483 patent/US9920111B2/en active Active
- 2015-10-01 AU AU2015234345A patent/AU2015234345C1/en active Active
-
2017
- 2017-11-20 AU AU2017264985A patent/AU2017264985B2/en active Active
-
2018
- 2018-01-08 HR HRP20180027TT patent/HRP20180027T1/hr unknown
- 2018-01-15 CY CY20181100043T patent/CY1121323T1/el unknown
- 2018-03-12 US US15/918,343 patent/US10239934B2/en active Active
-
2019
- 2019-02-14 US US16/275,936 patent/US10407493B2/en active Active
- 2019-07-17 US US16/513,859 patent/US10865234B2/en active Active
-
2020
- 2020-07-30 AU AU2020210242A patent/AU2020210242B2/en active Active
- 2020-10-28 US US17/082,322 patent/US11584789B2/en active Active
-
2023
- 2023-01-06 US US18/150,957 patent/US20230295278A1/en active Pending
- 2023-06-26 AU AU2023204017A patent/AU2023204017A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180027T1 (hr) | Protutijela za neutraliziranje virusa ljudske imunodeficijencije (hiv) | |
| USRE49037E1 (en) | Broadly neutralizing antibody and uses thereof | |
| Zwick et al. | Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41 | |
| Both et al. | Monoclonal antibodies for prophylactic and therapeutic use against viral infections | |
| WO2017133640A1 (en) | Broadly neutralizing antibodies against hiv-1 and use thereof | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| Zhang et al. | Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody | |
| Zhang et al. | Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library | |
| JP2018527952A5 (hr) | ||
| WO2012030904A3 (en) | Human immunodeficiency virus (hiv)-neutralizing antibodies | |
| Ingale et al. | Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies | |
| TW200846363A (en) | Novel human anti-R7V antibodies and uses thereof | |
| Valdez et al. | Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains | |
| CN106459186B (zh) | 针对hiv-1 v1v2 env区域的广谱中和性单克隆抗体 | |
| Zhou et al. | Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease | |
| WO2021046299A1 (en) | Methods for identification of antigen binding specificity of antibodies | |
| Kumar et al. | Isolation and characterization of cross-neutralizing human anti-V3 single-chain variable fragments (scFvs) against HIV-1 from an antigen preselected phage library | |
| Walker et al. | High-throughput B cell epitope determination by next-generation sequencing | |
| A Pantophlet | Antibody epitope exposure and neutralization of HIV-1 | |
| CN104004092A (zh) | 单基因编码的双或多价特异性抗hiv免疫粘附素 | |
| Luo et al. | Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques | |
| Simonich et al. | A diverse collection of B cells responded to HIV infection in infant BG505 | |
| Hu et al. | Identification of a CD4-binding site-directed antibody with ADCC activity from a chronic HIV-1B′-infected Chinese donor | |
| Zhang et al. | Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades | |
| Gong et al. | Candidate antibody-based therapeutics against HIV-1 |